The chaos of choice in large B-cell lymphoma: a call to harmonize first-line trials.

Harmonizing trial design and biomarker integration is essential to improve personalized treatment for large B-cell lymphoma patients.

• Why it matters: The rapid evolution of therapies has increased complexity and hindered clear clinical decision-making, risking fragmented and non-comparable treatment options.
• What they did: The authors propose a data-driven approach involving pooled analyses, standardized biomarker platforms, AI-based predictive models, and collaborative regulatory strategies to unify research efforts.
• The result: Implementing these strategies could enable precise, equitable, and effective therapies by aligning data, biology, and clinical decisions, ultimately improving patient outcomes.